Sentences with phrase «other immunotherapy»

Given the substantial increase in development activity and clinical success of other immunotherapy agents that followed, and in an effort to continue to provide maximum value to the rapidly evolving field, the direction of the CIC was re-set to become a «think tank» that would convene and tackle topics of importance to the continued development of cancer immunotherapies.

Once they find such tumor neo-antigens, as they're called, they could design other immunotherapy strategies that could target them.

NEW YORK AND SAN DIEGO (Sept. 3, 2014)-- The nonprofits Ludwig Cancer Research (Ludwig) and the Cancer Research Institute (CRI) announced today an agreement with VentiRx Pharmaceuticals Inc., a clinical stage biopharmaceutical company, to conduct a clinical trial with motolimod (VTX - 2337) combined with other immunotherapy agents available to Ludwig and CRI through other industry partnerships.

The researchers say the results warrant further development of neoantigen vaccines, both alone and in combination with other immunotherapy weapons such as checkpoint inhibitors.

Medical researchers are working hard to develop effective vaccines and other immunotherapy treatments for pancreatic cancer.

In animal studies, the technique more effectively targeted melanoma than other immunotherapy treatments.

If you have other immunotherapy stocks that you would like to discuss or you would like to discuss these further, then please add your thoughts in the comment section below.

The drugmaker has made other immunotherapy deals in the past.

In contrast to other immunotherapies that require admission to a hospital, this new therapeutic combination can be administered in an outpatient setting.

More than 500 clinical trials are underway to explore the impact of these and other checkpoint inhibitors on a dozen varieties of cancer, alone or with other immunotherapies, as well as conventional treatments.

«Our study reveals a previously unknown mechanism that we might be able to block to make tumors «visible» again to attacking immune cells, perhaps in combination with other immunotherapies,» says Miller, also an associate professor in the Department of Cell Biology.

«The advantage an optogentic approach has over other immunotherapies, which typically activate global immune responses, is that we now have the tools to closely monitor the dose and location of the treatment to mitigate potential side effects to healthy tissues.»

These chips could also be used to evaluate antibody drugs and other immunotherapies, which are difficult to test thoroughly in animals because the treatments are only designed to interact with the human immune system.

Adjuvants are substances that are either used alone or combined with other immunotherapies to boost the immune response.

Adjuvant immunotherapies are substances that are either used alone or combined with other immunotherapies to boost the immune response even more.

Most recently, CRI has launched a new «venture philanthropy» program called the Cancer Vaccine Acceleration Fund (CVAF) as a means to catalyze development of next - generation therapeutic cancer vaccines and other immunotherapies by helping to address the critical shortage of capital available for early stage clinical trials.

Researchers are investigating nanoparticles for delivery of immunostimulatory or immunomodulatory molecules in combination with chemo - or radiotherapy or as adjuvants to other immunotherapies.

Along with checkpoint blockade antibodies, vaccines, and other immunotherapies, BiTEs are helping to turn our immune system into a powerful defense against this disease.

Not exact matches

In the most recent of these reports (in the latest issue of Science), Dr. Jennifer Wargo, a surgeon and research scientist at M.D. Anderson, along with several dozen colleagues at other institutions, reveal that the composition of a patient's gut microbiota can significantly influence whether he or she responds to an immune checkpoint inhibitor — the type of cancer immunotherapy that releases the emergency brakes in the car analogy above.

«While we are disappointed CheckMate - 026 did not meet its primary endpoint in this broad patient population, we remain committed to improving patient outcomes through our comprehensive development program, including the ongoing Phase III CheckMate - 227 study exploring the potential of the combination of Opdivo plus [our other cancer immunotherapy] Yervoy for PD - L1 positive patients, and Opdivo plus Yervoy, or Opdivo plus chemotherapy in PD - L1 negative patients,» he added.

That's attached to the progress of sequencing technology, the ability to edit cells, and other gene editing approaches have been transformative in the immunotherapy world in recent years.

These types of drugs could potentially be used with other sorts of immunotherapies, which are all the rage in biopharma these days.

The Kamens claim the main thing that distinguishes their foundation from other brain tumor foundations is their focus on pediatric brain cancer specifically, as well as their close ties with pharmaceutical and biotech companies working in the fields of immunotherapy and target gene therapy.

While it has shown promise for some types of tumors and become standard of care for others, researchers are just beginning to explore how different immunotherapy technologies can be applied to brain cancer.

Other recent research into immunotherapy for glioblastoma points to promise as well as challenges.

One company already successfully launched an immunotherapy treatment, while the others are still being evaluated.

Risk Versus Reward: The Value of Cell Therapy for Patients and Investors Source: Streetwise Reports (4/25/18) The cell therapy space, encompassing disruptive new treatment including stem cell therapy, immunotherapy and gene editing, has begun to mature, with a handful of product approvals and others in late - stage development.

The cell therapy space, encompassing disruptive new treatment including stem cell therapy, immunotherapy and gene editing, has begun to mature, with a handful of product approvals and others in late - stage development.

A number of other small studies support this idea, known as «immunotherapy,» for overcoming various types of food allergies, but it's still unclear how long the effects last — it may be that people have to keep consuming the allergen regularly to avoid becoming allergic again — and exposing allergic individuals to their offending allergens can, of course, be risky.

Sergio Pastrana, executive director of the Cuban Academy of Sciences, called the symposium, plus a previous conference on neuroscience held in December 2015 and one on cancer immunotherapy in May 2016, opportunities for «scientists of both nations to get to know each other and create avenues that lead to more long - range exchanges.»

«First mathematical model that predicts immunotherapy success: Researchers also helped craft similar model to predict why some pancreatic cancer patients survive longer than others.»

The Austrian immunotherapy company IGENEON, among others, supported his internship financially.

The Austrian immunotherapy company IGENEON, among others, supported A.B.'s internship financially.

At Mayo, some immunologists work on basic research and others lean more toward the clinical applications of immunotherapy.

«There are certainly challenges to overcome for clinical application of this kind of immunotherapy, but the newly published data are an important milestone in immunotherapy targeting solid tumors that have eluded other treatments.»

This includes determining whether the drugs should be used earlier on in cancer treatment, finding biomarkers to predict response, and combining immunotherapy with other treatments.

The same rings true when immunotherapy is paired with other cancer treatments like chemotherapy, for example.

Roche has four biologic cancer immunotherapy molecules in clinical trials that could work in powerful combinations with each other or with current drugs, says William Pao, global head of oncology discovery in Basel.

Why do some patients respond well to the new cancer immunotherapies and others don't?

It's clear this is not going to cure every patient, but treatments that include immunotherapy are more effective than other options.

According to Rottenberg, this new immunotherapy has been only modestly successful when used on other frequent tumours such as breast cancer - also, it results in side - effects and enormous costs.

While clinical trials of such immunotherapies in other cancers have shown them to be highly effective in a subgroup of patients, the new study stands out because nearly all patients benefited from the treatment.

«Last week's vote represents 30 years» worth of work to find a new way to treat this devastating cancer and the start of a new era in using personalized immunotherapy to treat other types of cancers.»

The immunotherapy drug pembrolizumab — already FDA - approved for other forms of cancer - has been found to be effective in patients with metastatic triple negative breast cancer, according to an international clinical trial led by NYU Langone's Perlmutter Cancer Center.

These drugs work by targeting the PDL - 1 receptor — a known immunotherapy biomarker for lung and other cancers — to boost immune responses to the cancer.

Creticos says his team has also begun studies of other non-injectible forms of immunotherapy, including ragweed allergy drops, and treatment applications where the allergen is lightly pricked or inserted into the middle layers of the skin.

A handful of other companies are also in the field, working on therapies that treat diseases of the central nervous system or enhance cancer immunotherapy.

Other labs are pursuing immunotherapy, the use of check - point inhibitors, vaccination and efforts to increase sensitivity to radiotherapy.

Therefore, «this finding may represent a future therapeutic strategic to combine with other strategies, such as immunotherapy, chemotherapy or inhibitors against specific signalling routes of the tumour cells.»

The introduction of CRISPR, which is simpler and more efficient than other techniques, will probably accelerate the race to get gene - edited cells into the clinic across the world, says Carl June, who specializes in immunotherapy at the University of Pennsylvania in Philadelphia and led one of the earlier studies.